^
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
ICP-022
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
temsirolimus
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
ibrutinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
rituximab + bortezomib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
acalabrutinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
avapritinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
venetoclax + ibrutinib
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
bortezomib
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
venetoclax
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
rituximab + ibrutinib + lenalidomide
Sensitive: A2 - Guideline
ALK negative
Mantle Cell Lymphoma
brentuximab vedotin
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
VR-CAP
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
R-DHAP
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
R-DHAX
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
R-CVAD
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
R-GemOx
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
R-CHOP
Sensitive: A2 - Guideline
No biomarker
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: A2 - Guideline
CCR7 positive
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: B - Late Trials
ABCB1 mutation + VEGFA mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
VEGFA mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
ABCB1 mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
CCND1 overexpression
Mantle Cell Lymphoma
INCB50465
Sensitive: C2 – Inclusion Criteria
TP53 mutation
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: C2 – Inclusion Criteria
NLRC5 mutation
Mantle Cell Lymphoma
acalabrutinib
Resistant: C3 – Early Trials
B2M mutation
Mantle Cell Lymphoma
acalabrutinib
Resistant: C3 – Early Trials
CARD11 mutation
Mantle Cell Lymphoma
acalabrutinib
Resistant: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
rituximab + ibrutinib + lenalidomide
Sensitive: C3 – Early Trials
PD-L1 underexpression
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
CDKN2A deletion
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
Immunotherapy + lenalidomide
Resistant: C3 – Early Trials
ATM mutation
Mantle Cell Lymphoma
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
PRMT5 overexpression + MTAP deletion
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
CDKN2A deletion + MTAP deletion
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
HES1 overexpression
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: C3 – Early Trials
SOX11 expression
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: C3 – Early Trials
CTLA4 overexpression
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: C3 – Early Trials
ITK overexpression
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
NOTCH1 mutation
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
ARID1B deletion
Mantle Cell Lymphoma
temsirolimus
Resistant: C3 – Early Trials
DLGAP2 deletion
Mantle Cell Lymphoma
temsirolimus
Resistant: C3 – Early Trials
BIRC3 mutation
Mantle Cell Lymphoma
temsirolimus
Resistant: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
rituximab + lenalidomide
Sensitive: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
venetoclax + rituximab + lenalidomide
Sensitive: C3 – Early Trials
CD20 positive
Mantle Cell Lymphoma
GEN3013
Sensitive: C3 – Early Trials
TP53 overexpression
Mantle Cell Lymphoma
ibrutinib + bortezomib
Sensitive: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
rituximab + ibrutinib + EX-204
Sensitive: C3 – Early Trials
PIK3CD expression
Mantle Cell Lymphoma
BI 6727
Sensitive: D – Preclinical
ROR1 expression
Mantle Cell Lymphoma
VLS-101
Sensitive: D – Preclinical
MYC overexpression
Mantle Cell Lymphoma
TG-1701
Sensitive: D – Preclinical
IL6 elevation
Mantle Cell Lymphoma
TG-1701
Sensitive: D – Preclinical
IL2 elevation
Mantle Cell Lymphoma
TG-1701
Sensitive: D – Preclinical
IL2 elevation
Mantle Cell Lymphoma
umbralisib + TG-1701 + ublituximab
Sensitive: D – Preclinical
IL6 elevation
Mantle Cell Lymphoma
umbralisib + TG-1701 + ublituximab
Sensitive: D – Preclinical
TNFA elevation
Mantle Cell Lymphoma
umbralisib + TG-1701 + ublituximab
Sensitive: D – Preclinical
LY9 expression
Mantle Cell Lymphoma
T-lymphocyte cell therapy
Sensitive: D – Preclinical
BTK C481S
Mantle Cell Lymphoma
TG-1701
Sensitive: D – Preclinical
PIK3CG expression
Mantle Cell Lymphoma
copanlisib
Sensitive: D – Preclinical
PIK3CG expression
Mantle Cell Lymphoma
BI 6727
Sensitive: D – Preclinical
PIK3CG expression
Mantle Cell Lymphoma
copanlisib + BI 6727
Sensitive: D – Preclinical
PIK3CD expression
Mantle Cell Lymphoma
copanlisib
Sensitive: D – Preclinical
PIK3CD expression
Mantle Cell Lymphoma
copanlisib + BI 6727
Sensitive: D – Preclinical
PIK3CB expression
Mantle Cell Lymphoma
copanlisib
Sensitive: D – Preclinical
PIK3CB expression
Mantle Cell Lymphoma
BI 6727
Sensitive: D – Preclinical
PIK3CB expression
Mantle Cell Lymphoma
copanlisib + BI 6727
Sensitive: D – Preclinical
PIK3CA expression
Mantle Cell Lymphoma
copanlisib
Sensitive: D – Preclinical
PIK3CA expression
Mantle Cell Lymphoma
copanlisib + BI 6727
Sensitive: D – Preclinical
PIK3CA expression
Mantle Cell Lymphoma
BI 6727
Sensitive: D – Preclinical
BCL2L1 overexpression
Mantle Cell Lymphoma
venetoclax
Resistant: D – Preclinical
SYK overexpression
Mantle Cell Lymphoma
piceatannol
Sensitive: D – Preclinical
TP53 deletion
Mantle Cell Lymphoma
venetoclax
Resistant: D – Preclinical
CCND1 expression
Mantle Cell Lymphoma
palbociclib
Sensitive: D – Preclinical
ATM underexpression
Mantle Cell Lymphoma
olaparib
Sensitive: D – Preclinical
CCND1 expression + CDK4 expression
Mantle Cell Lymphoma
palbociclib
Sensitive: D – Preclinical
NOTCH1 mutation
Mantle Cell Lymphoma
Compound E
Sensitive: D – Preclinical
SAMHD1 mutation
Mantle Cell Lymphoma
fludarabine IV
Resistant: D – Preclinical
SAMHD1 mutation
Mantle Cell Lymphoma
cytarabine
Resistant: D – Preclinical
NRAS G13D
Mantle Cell Lymphoma
ASN007
Sensitive: D – Preclinical
BTK C481S
Mantle Cell Lymphoma
ibrutinib
Resistant: D – Preclinical
BTK C481S
Mantle Cell Lymphoma
SRX3262
Sensitive: D – Preclinical